1
Registered trials
0
Recruiting
1
Unique sponsors
1
Unique IMPs
0
Commercial trials
Drug classes (ATC)
L
Oncology (ATC L)
1
Mechanism of action (INN-stem analysis)
Checkpoint inhibitor (PD-L1)
1 substance
Phase II:
1
Phase II
1 trial-
EndedFrankfurter Institut Fuer Klinische Krebsforschung IKF GmbH AcademicDURVALUMAB
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH | Academic | 1 | Phase II | 0 |
New trials by year
2022
1